SynthesisObesity surgery2026
Effectiveness of Prophylactic Doses of Tranexamic Acid in Reducing Hemorrhagic Events in Bariatric Surgery: A Systematic Review and Meta-Analysis.
Synthesis in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postoperative bleeding is a major complication in bariatric surgery, contributing to increased morbidity, longer hospital stays, and healthcare costs. Tranexamic acid (TXA), an antifibrinolytic agent, has shown promise in reducing surgical blood loss in various specialties. However, there is still no consensus regarding its effectiveness and safety in bariatric surgery. We performed a systematic review and meta-analysis to evaluate the impact of prophylactic TXA on hemoglobin levels, procedural duration, and hospital length of stay in bariatric surgery patients. PubMed, Embase, and Cochrane Central were searched for randomized controlled trials (RCTs) and observational studies comparing TXA and non-TXA groups in bariatric surgery up to November 2024. Data were independently extracted by two reviewers, and risk of bias was assessed using ROBINS-I and RoB-2. Outcomes were assessed using random-effects models, with heterogeneity evaluated by I2 statistics. Sensitivity analyses and publication bias assessments were also performed. Nine studies (2 RCTs and 7 observational studies) involving 1,956 patients were included. TXA significantly improved hemoglobin levels (MD 0.46 g/dL; 95% CI 0.08-0.84; P = 0.02), reduced procedure duration (MD -9.70 min; 95% CI -14.79 to -4.61; P < 0.01), and shortened hospital length of stay (MD -0.19 days; 95% CI -0.31 to -0.07; P < 0.01). No significant increase in thrombotic events was observed. Sensitivity analyses confirmed the robustness of these findings despite high heterogeneity. Prophylactic TXA may significantly reduce perioperative bleeding (smaller hemoglobin decline), operative time, and length of hospital stay in bariatric surgery, without a signal of increasing thrombotic risks, but this should be interpreted with caution given small sample sizes and low event rates. These results support the integration of TXA into perioperative care protocols for bariatric surgery, offering potential benefits in patient outcomes and surgical efficiency.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.